Issue of Equity

29 September 2014

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Issue of Equity

Plethora Solutions Holdings plc (AIM: PLE) announces that it has received notice from Forest Nominees Limited to convert all £800,000 of its convertible loan notes into ordinary shares of 1p each ("Ordinary Shares"). Interest on the loan notes has been accrued in accordance with the restructuring announced on 18 March 2013 and an amount of £176,132 will have accrued to that date and be converted to new Ordinary Shares. In total 48,806,575 new Ordinary Shares will be issued at 2p per share, to satisfy the aggregate of £976,132 arising on the conversion.

Application has been made for the new Ordinary Shares issued on conversion of the loan notes to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place on 3 October 2014.

Following the issue and allotment of 48,806,575 Ordinary Shares connected with today's conversion of loan notes, the nominal value of the outstanding convertible debt issued by the Company will fall by £800,000 to £1,969,595.

Following Admission, the Company will have 681,011,729 Ordinary Shares in issue. This figure may be used by shareholders in Plethora as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

About PSD502™ & Premature Ejaculation:

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. In two large, double blind, pivotal Phase III studies PSD502™ showed a highly significant and clinically meaningful effect increasing mean intravaginal ejaculatory latency time at baseline from 0.5 minutes to 3.2 minutes at week 12. 87% of the patients in the studies were considered as responders with the product being well tolerated with no significant safety issues. PSD502™ also showed positive effects across a wide range of other parameters including partner satisfaction. PSD502™ was approved by the European Commission in November 2013.

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20% to 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

The premature ejaculation market offers significant potential for development and growth given the absence of any widely approved pharmaceutical therapy with good patient acceptance. As a result an effective drug therapy for premature ejaculation may have a commercial potential comparable to erectile dysfunction drugs.

About Plethora

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE LN). Further information is available at www.plethorasolutions.co.uk 

Plethora is focused on commercializing PSD502™ for the treatment of premature ejaculation with strategic marketing partners and obtaining NDA approval for PSD502™ with the FDA.

Enquiries: